A retrospective comparative study of IFX (5 mg/kg at weeks 0, 2, and 6) and adalimumab (40 mg every other week) showed that IFX, in 20 patients with severe, recalcitrant HS, performed better in Sartorius score, DLQI, reduction of ESR and CRP, patient and doctor global assessment, and duration of efficacy [189]. This evidence concerns the gene CRP and histiocytic sarcoma.